Targeted Delivery of Drug to Liver Carcinoma Using Artificial Glycopolypeptide Micelle

Pharmaceutical Regulatory Affairs: Open Access

ISSN: 2167-7689

Open Access

Short Communication - (2022) Volume 11, Issue 7

Targeted Delivery of Drug to Liver Carcinoma Using Artificial Glycopolypeptide Micelle

Sara Cirone*
*Correspondence: Sara Cirone, Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi 110070, India, Email:
Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi 110070, India

Received: 01-Jul-2022, Manuscript No. pbt-22-75941; Editor assigned: 02-Jul-2022, Pre QC No. P-75941; Reviewed: 16-Jul-2022, QC No. Q-75941; Revised: 22-Jul-2022, Manuscript No. R-75941; Published: 30-Jul-2022 , DOI: 10.37421/2167-7689.2022.11.322
Citation: Cirone, Sara and Eales Penel. “Targeted Delivery of Drug to Liver Carcinoma Using Artificial Glycopolypeptide Micelle” Pharmaceut Reg Affairs 11 (2022): 322.
Copyright: © 2022 Cirone S, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Chemotherapy is generally applied in malignant growth treatment and shows specific predominance contrasted and medical procedure and radiotherapy. However medicates with various systems have been produced for different malignancies, patients actually experience extreme aftereffects because of the undesired dispersion of free medications in typical organs. Doxorubicin (DOX), for instance, is a wide range chemotherapy drug applied in many kinds of malignancies, e.g., hepatic disease, bosom disease, ovarian malignant growth, cellular breakdown in the lungs, and delicate tissue sarcoma [1,2]. Nonetheless, the antitumor utilization of DOX is to a great extent thwarted by its huge deformities, for example, unfortunate objective person, low dissolvability, short blood flow, heart harm, etc. On the other hand, designated chemotherapeutic frameworks that cannot just increment the medication gathering at growth destinations yet additionally decline the medication dispersion in typical organs are required earnestly [3]. The nanosized vehicles can gather at growth locales through improved penetrability and maintenance (EPR) impacts; second, in the wake of being altered with explicit ligands, these nanocarriers can perceive the cancer cells through unambiguous ligand-receptor cooperation. This can gives an amazing chance to beat the inherent furthest reaches of traditional disease treatments. Lately, glycopolypeptide has drawn in a lot of consideration in clinical materials as a result of its extraordinary sub-atomic creation and comparative design to regular glycoproteins. Normally, oligosaccharides filled in as sign particles toward the finish of glycoproteins. Simultaneously, the presence of oligosaccharides keeps the proteases from straightforwardly reaching the polypeptide to diminish the debasement of glycopolypeptide and work on the strength of the materials [4]. All the more significantly, a few monosaccharides or polysaccharides, for example, α-lactose (Lac), sialic corrosive (SA), hyaluronic corrosive (HA), show the capacity to target cancer cells. Hence, glycopolypeptide may be an ideal possibility for designated chemotherapy.


The glycopolypeptide could self-collect into nano-sized micelles by means of hydrophobic cooperation to go about as a transporter. Free DOX was picked as a model medication and afterward stacked into the center of GPM through solid π-π cooperation with the phenylalanine block [5]. The DOXstacked GPM (i.e., GPM/DOX) showed unrivaled properties contrasted and free DOX: (1) Inferable from the appropriate size, GPM/DOX could amass at the growth locales through EPR impact; (2) through the π-π stacking impact, the medication stacking content (DLC) of GPM was clearly improved; (3) the polymer micelle could target hepatic cells effectively through particular acknowledgment among Lac and ASGP-R. The compound designs of these polymers were affirmed with a 500 MHz Avance III HD atomic attractive reverberation spectrometer and a fourier change infrared spectrometer. The DOX fluorescence in the liver was higher in the mice of the free DOX bunch than those in the GPM/DOX bunch, which uncovered that free DOX was processed all the more rapidly by the liver [6]. In like manner, more DOX dispersion was seen in the hearts and kidneys of mice treated with free DOX as a sign of more grounded poisonousness toward these two organs. Notwithstanding, less fluorescence power in the heart or kidney was found in the GPM/DOX bunch. It merited seeing that the mice directed with the GPM/ DOX micelle showed a lot more grounded fluorescence force of DOX at growth destinations than those in the free DOX bunch.

The antitumor impacts of GPM/DOX were confirmed by histopathology and immunohistochemistry (IHC) examinations in mice cancer tissues. The cancer tissue areas were ready with hematoxylineosin (H&E) staining. As displayed in Figure 4C (H&E), the cancer cells of the benchmark group developed effectively, while the growth cells started to become apoptotic in the free DOX and GPM/DOX gatherings. Moreover, the growth corruption regions were the biggest in all gatherings, and around 1.2-overlap bigger than that of free DOX bunch [7,8]. The information of the cancer corruption regions were steady with growth restraint rates overall. A multiplying cell atomic antigen (PCNA) stain was utilized to survey the cancer cell expansion capacity. The in vivo securities of GPM/DOX were additionally concentrated by histopathology. The obsessive areas of primary organs were stained with H&E. As displayed in Figure S4, the free DOX and GPM/DOX bunches showed obsessive changes in H&E somewhat. The principal changes are as per the following: (I) annihilation of myocardial construction and aggravation; (ii) the renal case depression shrank or vanished. The harm levels to the hearts or kidneys of mice in the free DOX bunch were more serious than those in the GPM/DOX bunch, which further affirmed that GPM/DOX had higher security than free DOX [9,10].


Glycopolypeptide-based micelle was ready for designated chemotherapy of hepatic danger. The GPM/DOX could improve drug gathering in growths and lessen the dispersion in nontargeted tissues. Specifically, the medication focus in heart in GPM/DOX bunches were just a single third of that in the free DOX bunch, fundamentally decreasing cardiotoxicity of DOX, which surely showed a fantastic antitumor impact and a high security in vivo. The straightforward interaction and great execution of GPM/DOX give likelihood to clinical application.



Conflicts of Interest

The Author declared no conflict of Interest.


  1. Xu, Weiguo, Jianxun Ding, Chunsheng Xiao and Lingyu Li, et al. "Versatile preparation of intracellular-acidity-sensitive oxime-linked polysaccharide-doxorubicin conjugate for malignancy therapeutic." Biomaterials 54 (2015): 72-86.
  2. Google Scholar, Crossref, Indexed at

  3. Zhang, Junji, Youxin Fu, Hai-Hao Han and Yi Zang, et al. "Remote light-controlled intracellular target recognition by photochromic fluorescent glycoprobes." Nat Commun 8 (2017): 1-9.
  4. Google Scholar, Crossref, Indexed at

  5. Wang, Hangxiang, Jianmei Chen, Chang Xu and Linlin Shi, et al. "Cancer nanomedicines stabilized by π-π stacking between heterodimeric prodrugs enable exceptionally high drug loading capacity and safer delivery of drug combinations." Theranostics 7 (2017): 3638.
  6. Google Scholar, Crossref, Indexed at

  7. Zdobnova, Tatiana, Evgeniya Sokolova, Oleg Stremovskiy and Dmitry Karpenko, et al. "A novel far-red fluorescent xenograft model of ovarian carcinoma for preclinical evaluation of HER2-targeted immunotoxins." Oncotarget 6 (2015): 30919.
  8. Google Scholar, Crossref, Indexed at

  9. Pati, Debasis, Soumen Das, Naganath G. Patil and Nimisha Parekh, et al. "Tunable nanocarrier morphologies from glycopolypeptide-based amphiphilic biocompatible star copolymers and their carbohydrate specific intracellular delivery." Biomacromolecules 17 (2016): 466-475.
  10. Google Scholar, Crossref, Indexed at

  11. Cagel, Maximiliano, Estefanía Grotz, Ezequiel Bernabeu and Marcela A. Moretton, et al. "Doxorubicin: nanotechnological overviews from bench to bedside." Drug Discov Today 22 (2017): 270-281.
  12. Google Scholar, Crossref, Indexed at

  13. Chen, Jinjin, Jianxun Ding, Yucai Wang and Jianjun Cheng, et al. "Sequentially responsive Shell‐stacked nanoparticles for deep penetration into solid tumors." Adv Mater 29 (2017): 1701170.
  14. Google Scholar, Crossref, Indexed at

  15. Khawar, Iftikhar Ali, Jung Ho Kim, and Hyo-Jeong Kuh. "Improving drug delivery to solid tumors: priming the tumor microenvironment." J Control Release 201 (2015): 78-89.
  16. Google Scholar, Crossref, Indexed at

  17. Pan, Sheng, Teresa A. Brentnall, and Ru Chen. "Glycoproteins and glycoproteomics in pancreatic cancer." World J Gastroenterol 22 (2016): 9288.
  18. Google Scholar, Crossref, Indexed at

  19. Bode, Lars, and Evelyn Jantscher-Krenn. "Structure-function relationships of human milk oligosaccharides." Adv Nutr 3 (2012): 383S-391S.
  20. Google Scholar, Crossref, Indexed at

Awards Nomination

50+ Million Readerbase

Journal Highlights

Google Scholar citation report
Citations: 471

Pharmaceutical Regulatory Affairs: Open Access received 471 citations as per Google Scholar report

Pharmaceutical Regulatory Affairs: Open Access peer review process verified at publons

Indexed In

arrow_upward arrow_upward